Barinthus Biotherapeutics (BRNS) Short Interest Ratio & Short Volume → Does this make you sick? (From Allegiance Gold) (Ad) Free BRNS Stock Alerts $2.24 -0.08 (-3.45%) (As of 03:50 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Barinthus Biotherapeutics Short Interest DataCurrent Short Volume19,000 sharesPrevious Short Volume14,100 sharesChange Vs. Previous Month+34.75%Dollar Volume Sold Short$38,950.00Short Interest Ratio / Days to Cover0.8Last Record DateApril 30, 2024Outstanding Shares38,920,000 sharesFloat Size35,700,000 sharesShort Percent of Float0.05%Today's Trading Volume9,296 sharesAverage Trading Volume19,212 sharesToday's Volume Vs. Average48% Short Selling Barinthus Biotherapeutics ? Sign up to receive the latest short interest report for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBRNS Short Interest Over TimeBRNS Days to Cover Over TimeBRNS Percentage of Float Shorted Over Time Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit Barinthus Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202419,000 shares $38,950.00 +34.8%0.1%0.8 $2.05 4/15/202414,100 shares $37,252.20 +39.6%0.0%0.6 $2.64 3/31/202410,100 shares $24,038.00 -15.1%0.0%0.5 $2.38 3/15/202411,900 shares $29,393.00 -3.3%0.0%0.8 $2.47 2/29/202412,300 shares $34,809.00 -12.8%0.0%0.8 $2.83 2/15/202414,100 shares $34,968.00 -55.8%0.0%1.2 $2.48 1/31/202431,900 shares $87,725.00 No Change0.1%1.3 $2.75 BRNS Short Interest - Frequently Asked Questions What is Barinthus Biotherapeutics' current short interest? Short interest is the volume of Barinthus Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 19,000 shares of BRNS short. 0.05% of Barinthus Biotherapeutics' shares are currently sold short. Learn More on Barinthus Biotherapeutics' current short interest. What is a good short interest ratio for Barinthus Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BRNS shares currently have a short interest ratio of 1.0. Learn More on Barinthus Biotherapeutics's short interest ratio. What is a good short interest percentage for Barinthus Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.05% of Barinthus Biotherapeutics' floating shares are currently sold short. Is Barinthus Biotherapeutics' short interest increasing or decreasing? Barinthus Biotherapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 19,000 shares, an increase of 34.8% from the previous total of 14,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Barinthus Biotherapeutics' float size? Barinthus Biotherapeutics currently has issued a total of 38,920,000 shares. Some of Barinthus Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Barinthus Biotherapeutics currently has a public float of 35,700,000 shares. How does Barinthus Biotherapeutics' short interest compare to its competitors? 0.05% of Barinthus Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Barinthus Biotherapeutics: Anixa Biosciences, Inc. (2.08%), Spero Therapeutics, Inc. (0.87%), BeyondSpring Inc. (9.99%), Chimerix, Inc. (1.71%), Milestone Pharmaceuticals Inc. (0.81%), Cue Biopharma, Inc. (10.20%), Oncolytics Biotech Inc. (1.14%), Adagene Inc. (0.04%), ProPhase Labs, Inc. (1.88%), YS Biopharma Co., Ltd. (0.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Barinthus Biotherapeutics stock? Short selling BRNS is an investing strategy that aims to generate trading profit from Barinthus Biotherapeutics as its price is falling. BRNS shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Barinthus Biotherapeutics? A short squeeze for Barinthus Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BRNS, which in turn drives the price of the stock up even further. How often is Barinthus Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BRNS, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Anixa Biosciences Short Interest Data Spero Therapeutics Short Interest Data BeyondSpring Short Interest Data Chimerix Short Interest Data Milestone Pharmaceuticals Short Interest Data Cue Biopharma Short Interest Data Oncolytics Biotech Short Interest Data Adagene Short Interest Data ProPhase Labs Short Interest Data YS Biopharma Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BRNS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News